 |
|
Phenotypic Variability Due to a Novel Glu292Lys Variation in Exon 8 of the BEST1 Gene Causing Best Macular Dystrophy
Elliott H. Sohn, MD;
Peter J. Francis, MD, PhD;
Jacque L. Duncan, MD;
Richard G. Weleber, MD;
David A. Saperstein, MD;
Donald F. Farrell, MD;
Edwin M. Stone, MD, PhD
Arch Ophthalmol. 2009;127(7):913-920.
ABSTRACT
Objective To study the phenotypic characteristics of patients with a novel p.E292K mutation in BEST1.
Methods Affected individuals underwent ophthalmic examination and testing that included photography, autofluorescence, optical coherence tomography, and electrophysiological testing. Their DNA was analyzed for BEST1 mutations.
Results Five patients aged 5 to 59 years who expressed the p.E292K mutation in BEST1 were identified in 3 families. Electro-oculographic light-rise was subnormal in all probands and carriers. Carriers had normal findings from fundus examination, multifocal electroretinography, and visual acuity, and were emmetropic or myopic. Only probands had hyperopia and fundus findings typical of Best macular dystrophy. Optical coherence tomography of vitelliform lesions demonstrated retinal pigment epithelium elevation without subretinal fluid; atrophic lesions exhibited disruption of the hyperreflective outer retina–retinal pigment epithelium complex. Intense hyperautofluorescence correlated with the vitelliform lesion.
Conclusions Patients with the Glu292Lys variation in BEST1 exhibit intrafamilial and interfamilial phenotypic variability. A disproportionate fraction (26%) of Best disease–causing mutations occurs in exon 8, suggesting that the portion of protein encoded by this exon (amino acids 290-316) may be especially important to bestrophin's function. Relatively good visual acuity with vitelliform lesions can be explained by preservation of the outer retina, demonstrated by optical coherence tomography.
Clinical Relevance A novel mutation in this region of BEST1 carries implications for disease pathogenesis.
INTRODUCTION
Best macular dystrophy (BMD) is an autosomal dominant condition caused by mutations in the BEST1 gene (OMIM 607854).1-2 Mutations in this gene result in a defective protein product, bestrophin, that localizes to the basolateral membrane of the retinal pigment epithelium (RPE)3 and has been associated with conductance abnormalities in a family of chloride channels4-5 and voltage-gated calcium channels.6-8 These alterations may account for the diminished light peak to dark trough ratio (Arden ratio typically  1.5) of the electro-oculogram (EOG) characteristic of BMD; full-field electroretinography (ffERG) findings are typically normal.9-10
The fundus findings associated with BEST1 mutations are quite varied and include a normal fundus appearance with an EOG that shows abnormalities; vitelliform lesions with a "sunny-side–up" egg yolk appearance in the central macula; a "pseudohypopyon" in which the yellow material gravitates inferiorly in the sub-RPE space; a "scrambled-egg" appearance characterized by yellowish subretinal deposits admixed with patches of hyperpigmentation and atrophy of the RPE; geographic atrophy; nodular subretinal gliosis centered on fixation; and, rarely, choroidal neovascularization.11 Visual acuity is often preserved in at least 1 eye throughout life, with more substantial visual loss occurring when BMD is complicated by choroidal neovascularization12-14 or extensive geographic atrophy.
Newer diagnostic techniques have refined our understanding of the anatomy of the macular lesions seen in patients with Best disease.15-20 For example, one of the first optical coherence tomographic (OCT) studies in these patients showed that the vitelliform material may lie between the outer retina and the RPE.21 Increased fluorescence of vitelliform fundus lesions on fundus autofluorescence (AF)22-23 images may be due to enhanced accumulation of fluorophores such as A2E.18
Although the precise structure of the protein has yet to be elucidated, it has been hypothesized that bestrophin has 4 transmembrane domains with amino and carboxyl terminals located in the cytoplasm. Most of the described BEST1 mutations causing BMD have been missense mutations,1-2,22, 24-40 and a disproportionate fraction of these mutations occurs in exon 8, suggesting that the portion of the protein encoded by this exon may be especially critical to its function. At the time of this writing, the Carver Nonprofit Genetic Testing Laboratory has observed 155 instances of 84 different BEST1 mutations in probands affected with Best disease, and 22 of these mutations (26%) lie within exon 8 (Tyler Kinnick, PhD, and E.M.S., unpublished data, 2008). Additional evidence of the functional importance of this portion of the protein is that exon 8 is highly conserved among the BEST1 orthologs of Caenorhabditis elegans, Drosophila melanogaster, and mice.2 In addition, a functional analysis of an exon 8 variant (Q293H) in human embryonic kidney cells revealed a severe reduction of chloride current that behaved in a dominant negative manner.27
In the present study, we identified individuals from 3 apparently unrelated families with a missense mutation in BEST1 causing a change at position 292 of glutamic acid to lysine. Clinical characterization including AF, OCT, and ffERG and multifocal ERG (mfERG) of these individuals demonstrates highly variable expression between individuals as well as intrafamilial variability with nonpenetrance of fundus findings in 2 consecutive generations.
METHODS
Three probands (aged 5-59 years) from 3 unrelated families were identified by characteristic fundus findings and abnormal Arden ratio on EOG. Family members of the 5-year-old boy were also examined, and electrophysiology was performed. After informed consent was obtained, blood samples were taken for DNA extraction, and subsequent mutation screening of BEST1 was performed at the John and Marcia Carver Nonprofit Genetic Testing Laboratory in Iowa City, Iowa. The protocol adhered to the tenets of the Declaration of Helsinki and was approved by the institutional review boards of the institutions involved.
A full medical history was taken and ophthalmic examination was performed. Patients underwent digital color fundus photography. The AF images of the 54-year-old subject were obtained using a TopCon 50EX digital fundus camera equipped with AF filters purchased from Ophthalmic Imaging Systems (Sacramento, California), similar to a system previously described.41-42 The OCT images were obtained using the Stratus III (Stratus OCT 4.0.2 software; Zeiss Instruments, Dublin, California). Electrophysiological assessment included ffERG and EOG, using recording methods laid out by International Society for Clinical Electrophysiology of Vision (ISCEV) standards and recommendations for electroretinography43-44 and EOG.43 The mfERG was performed in 4 cases according to guidelines that have been described elsewhere.41, 45
RESULTS
Mutation analysis revealed a missense variation resulting in a change of glutamic acid to lysine at amino acid position 292 in BEST1 in all probands and obligate carriers. Genotyping of 4 informative short tandem repeat polymorphisms at the BEST1 locus revealed a distinctly different disease-associated haplotype in family 1, strongly suggesting that the Glu292Lys mutation in that family occurred independently (data not shown). Summaries of the clinical findings for patients in this study are shown in the Table.
|
|
|
|
Table. Summary of Clinical Findings in 3 Families of Patients With the Glu292Lys BEST1 Variation
|
|
|
PROBAND 1 AND FAMILY MEMBERS
The parents of a 5-year-old boy noted intermittent convergent strabismus in the child for 8 weeks. Refractive error of +5.25 diopter spheres OU resulted in orthophoria with best-corrected visual acuity of 20/40 OU. His irides were green. Anterior segment examination, including anterior chamber depth, was within normal limits. Fundus examination revealed bilateral central vitelliform lesions (Figure 1, A and B). The ffERG was normal and EOG revealed Arden ratios of 1.1 OD and 1.4 OS. The OCT showed a discrete elevation of RPE and widening of the hyperreflective signal from the outer retina–RPE complex (Figure 1, C and D).
|
|
|
|
Figure 1. Fundus photographic and ocular coherence tomographic (OCT) images of proband 1. A and B, Fundus shows well-demarcated vitelliform lesions in the central macula. C and D, Corresponding OCT sections show elevation at the level of the retinal pigment epithelium, with preservation of the outer retinal layer.
|
|
|
The asymptomatic mother, who is of Scandinavian, Irish, and German descent, and the father, who is of French, German, and Norwegian descent, both had visual acuity of 20/20 without correction and normal fundus examination. However, EOG of the 30-year-old mother revealed Arden ratios of 1.2 OD and 1.3 OS. Her ffERG and mfERG scans showed no abnormalities. Genetic testing of the mother revealed that she had the same mutation in BEST1 Glu292Lys as her son.
This led to examination and testing of other family members (Figure 2) to further characterize the inheritance pattern. The proband's maternal grandfather, aged 57 years, was asymptomatic, with best-corrected visual acuity of 20/20. He had Arden ratios of 1.3 OU, and his ffERG and mfERG showed no abnormalities. Manifest refraction was –0.75 + 1.00@055 OD, –1.00 + 1.00@180 OS. His intraocular pressure was 14 mm Hg OU, and irides were hazel. His anterior chamber depth was normal. The crystalline lens was clear. Posterior segment examination revealed rare RPE changes but no vitelliform lesion or atrophy.
|
|
|
|
Figure 2. Pedigree of proband 1 (indicated by shaded box) demonstrates lack of penetrant fundus findings and hyperopia in carriers. Wt indicates wild type; yo, years old.
|
|
|
In addition, EOG testing of the above proband and asymptomatic carriers revealed prolonged light-peak slow oscillation, consistent with previously described findings in humans46 and animals47 with BMD.
PROBAND 2
The patient is a 54-year-old man of East Indian descent who was referred for reduced vision in the right eye for the past 10 years. His family history was unremarkable for similar vision problems. His best-corrected visual acuity was 20/200 (eccentric) OD and 20/20 OS. His refractive error was +2.25 + 0.75@180 OD, +1.75 + 0.75@165 OS. His intraocular pressure was 12 mm Hg OD and 14 mm Hg OS.
Anterior segment examination revealed brown irides and normal anterior chamber depth. Fundus examination revealed a central circumscribed area of atrophy in the right eye and a vitelliform lesion in the left eye (Figure 3, A and B). Both eyes exhibited deep fleck-like changes nasal to the disc and along the temporal arcades. The AF images of the right eye (Figure 3E) showed a central macular hypoautofluorescent lesion that corresponded to the area of atrophy on fundus examination with patches of increased AF, especially in the periphery of the lesion. Autofluorescence of both eyes allowed better visualization of the fleck-like lesions around the disc and arcades, exhibiting mixed hyperautofluorescence and hypoautofluorescence that was confluent in many areas. The AF images of the left eye (Figure 3F) showed a central area of homogenously increased autofluorescence corresponding to the vitelliform lesion. Optical coherence tomographic imaging (Figure 3C) revealed increased backscatter from the underlying sclera in the region of RPE atrophy with some irregular disruptions in the outer retina–RPE complex at the edges of the atrophic lesion in the right eye; OCT images in the left eye (Figure 3D) showed discrete elevation of the RPE without discontinuity of the hyperreflective outer retina–RPE complex.
|
|
|
|
Figure 3. Fundus photographic, ocular coherence tomographic (OCT), and autofluorescence (AF) images of proband 2. A and B, Fundus photographs demonstrate central atrophy of the right eye and a vitelliform lesion of the left eye. Both exhibit fleck-like changes nasal to the disc and around the arcades. C, OCT of the right eye reflects retinal pigment epithelium (RPE) atrophy, with disruption in the outer retina–RPE complex. D, OCT of the left eye shows discrete RPE elevation. E, AF of the right eye demonstrates a central hypoautofluorescent lesion. Fleck-like lesions around the disc and arcades reveal mixed hyperautofluorescence and hypoautofluorescence in both eyes. F, AF of the left eye shows central hyperautofluorescence corresponding to the vitelliform lesion.
|
|
|
Electrophysiological assessment revealed an Arden ratio of 1.5 OD and 1.3 OS. The ffERG was normal. Fixation was not stable enough to permit reliable mfERG recording using a pupil camera in the right eye, but mfERG of the left eye demonstrated reduced responses from the central 1° to 5° OS (Figure 4) with relative preservation of the response amplitude and timing from the surrounding macula.
|
|
|
|
Figure 4. Multifocal electroretinography of the left eye of proband 2 demonstrates reduced responses from the central 1° to 5° OS with relative preservation of the response amplitude and timing from the surrounding macula.
|
|
|
PROBAND 3
This 59-year-old woman of Norwegian and Jewish descent with green irides was found on routine examination 22 years earlier to have fundus findings suspicious for BMD. Two sisters and a nephew are thought to have BMD, and while her mother had vision problems, no diagnosis had been made at the time of her death. Ocular history was significant for hyperopia and laser peripheral iridotomy in both eyes for occludable angles. Medical history was significant for well-controlled diabetes mellitus type 2, polymyalgia rheumatica, reflux disease, and osteoarthritis.
Visual acuity was 20/70 OD with +1.25 + 0.50@170 and 20/50 OS with +1.00 + 0.25@010. On biomicroscopy, the laser peripheral iridotomies were patent and there was mild nuclear sclerosis in both eyes. Fundus examination revealed bilateral central atrophy with few drusen in the midperiphery (Figure 5, A and B). Corresponding to the area of atrophy seen on examination, OCT revealed attenuation of the outer retina and hyperreflectivity of the RPE with increased signal posterior to the RPE (Figure 5, C and D).
|
|
|
|
Figure 5. Fundus photographic and optical coherence tomographic (OCT) images of proband 3. A and B, Fundus reveals bilateral central atrophy with few drusen in the midperiphery of both eyes. C and D, OCT indicates areas of atrophy seen with increased signal posterior to the retinal pigment epithelium and attenuation of the outer retina.
|
|
|
The Arden ratio was 1.2 OD and 1.1 OS. Her ffERG showed no abnormalities; mfERG (Figure 6) exhibited attenuation of amplitude and latency delay that was most prominent in the central macula with relative sparing of the peripheral macula.
|
|
|
|
Figure 6. Multifocal electroretinography of proband 3 demonstrates attenuation of amplitude and latency delay most prominent in the central macula, with relative sparing of the periphery.
|
|
|
COMMENT
The BEST1 gene, together with BEST2, BEST3, and BEST4, are part of a closely related gene family characterized by several transmembrane-spanning domains and an invariant arginine-phenylalanine-proline motif. These 4 human genes are believed to be orthologous to a gene in C elegans that shares a highly conserved 26–amino acid sequence beginning at position 289.48 Three lines of evidence support the idea that the novel bestrophin variation reported here is disease causing. First, the glutamic acid residue normally present at position 292 is highly conserved evolutionarily. Second, glutamic acid is negatively charged at neutral pH, while the lysine residue found in affected individuals is positively charged. This is the most extreme charge difference possible for a point mutation. Finally, presence of the mutation in 3 unrelated families with different bestrophin haplotypes suggests that the variation arose more than once. This makes it very likely that Glu292Lys is the disease-causing variation in the gene and not simply a non–disease-causing polymorphism in linkage disequilibrium with a true disease-causing mutation nearby. Mutations are common in the region of the human BEST1 gene encoding amino acids 290 through 316, suggesting that this portion of the protein is critical to its function.
In the present study, we performed a detailed clinical and electrophysiological evaluation of 5 subjects from 3 unrelated families who share a previously undescribed missense mutation in BEST1, a change from glutamic acid to lysine at amino acid position 292. We observed variable expressivity in our cohort of patients. Only the reduced light peak on the EOG was completely penetrant. Hyperopia was also found in all probands but was distinctly absent in carriers. Though it is tempting to attribute this to reduced axial length from the elevated fundus lesion, hyperopia was also found in our patients with flat atrophic retinas, as demonstrated on OCT. Moreover, similar degrees of hyperopia were seen in proband 2 despite atrophy in one eye and a vitelliform lesion in the other. Hyperopia is a common finding in patients with BMD22, 49 and is found in other conditions caused by mutations in BEST1 such as autosomal dominant vitreoretinochoroidopathy50 and autosomal recessive bestrophinopathy.51 Findings of hyperopia in probands may be related to genetic modifiers such as microphthalmia-associated transcription factor (MITF).52-53 Interactions between MITF and BEST1 have not been fully explored. While it is unclear whether our probands were hyperopic before the development of lesions, it would be interesting to compare the prevalence of hyperopia in probands and carriers and determine whether hyperopia is a predictive factor for developing vitelliform lesions. Such a finding would have implications for prognosis and counseling of patients and families. The lack of hyperopia among carriers in our study could indicate a favorable prognostic sign in patients with this mutation.
While proband 1 had mildly diminished visual acuity despite the presence of vitelliform lesions, both his mother and his 57-year-old maternal grandfather had relatively normal fundi despite diminished EOG and the presence of the Glu292Lys variation. In addition to emmetropia, normal visual acuity, and lack of fundus lesions, both carriers also had normal ffERG and mfERG responses. This appears to be the first demonstration of nonpenetrant fundus findings in 2 consecutive generations with a confirmed BEST1 mutation. Given the early age at which large vitelliform lesions are typically observed, it seems more likely that the variable clinical findings among patients carrying the same BEST1 variation are due to modifying genes rather than environmental factors.
The results of OCT and AF performed in our patients allow us to speculate on the nature of the vitelliform lesion, for which histopathology in a human eye has not been performed. Models of BEST1 mutations in dogs54 and mice47 are not adequate for this purpose, as these animals do not develop typical vitelliform lesions. Human eyes with the scrambled egg appearance have abnormally high amounts of lipofuscin.17 Studies in elderly individuals homozygous or heterozygous for mutations in BEST1 have demonstrated modestly elevated levels of A2E compared with controls.18 However, it is unknown whether A2E is a by-product of the latter stages of disease or whether other components of lipofuscin contribute to the hyperautofluorescent appearance in early stages. Intense hyperautofluorescence corresponding to the vitelliform lesion was seen in the left eye of proband 2, but a circumscribed patch of decreased AF corresponded to the atrophic lesion with speckled increased AF. In light of histopathological studies of late BMD,15-16 this loss of AF is likely due to irregularities in the RPE cell monolayer with secondary loss of photoreceptor outer segment turnover correlating with the poor level of vision in this eye. Relatively preserved visual acuity was seen in probands 1 and 2, with vitelliform lesions causing RPE elevations. Notably, OCT revealed no evidence of serous detachment in our patients, as recently reported in patients with BMD studied with spectral domain OCT.55 This contrasts with other studies of autofluorescent vitelliform lesions that showed fluid between the RPE and outer retina.21, 56 One hypothesis accounting for our findings is that mutated bestrophin in RPE, which likely contains lipofuscin in the vitelliform stage, causes impaired transport of fluid to the choroid, resulting in separation of the RPE from the choroid. Progression causes defective pumping of subretinal fluid to the RPE, resulting in the detachment of the outer retina from RPE that was shown in previous studies of eyes with more advanced disease.
Patients with Glu292Lys variation in BEST1 exhibit intrafamilial and interfamilial phenotypic variability. Thus, it is important for clinicians to realize that identification of the variation by genetic testing does not always portend the eventual development of macular disease. Our findings support the idea that the portion of the protein consisting of amino acids 290 through 316 may be critical to the function of bestrophin. Relatively good visual acuity with vitelliform lesions can be explained by preservation of the outer retina demonstrated by OCT.
AUTHOR INFORMATION
Correspondence: Elliott H. Sohn, MD, Doheny Eye Institute, 1450 San Pablo St, Ste 3608, Los Angeles, CA 90033 (elliott.sohn{at}gmail.com).
Submitted for Publication: December 6, 2008; final revision received January 23, 2009; accepted February 3, 2009.
Financial Disclosure: None reported.
Funding/Support: This study was supported in part by Research to Prevent Blindness (Drs Francis, Duncan, and Weleber); Foundation Fighting Blindness (Drs Sohn, Francis, Duncan, and Weleber); National Eye Institute grant EY002162, That Man May See, Inc, the Bernard A. Newcomb Macular Degeneration Fund, Hope for Vision, and the Karl Kirchgessner Foundation (Dr Duncan); the Curran Fund for Research on Best Disease (Dr Weleber); and the Howard Hughes Medical Institute (Dr Sohn).
Additional Contributions: The authors thank Karmen Trzupek, MS, CGC, Susan Clarke, MLIS, Jean Andorf, and Becky Johnston for their excellent assistance.
Author Affiliations: Doheny Eye Institute and Department of Ophthalmology, Keck School of Medicine of the University of Southern California, Los Angeles (Dr Sohn); Departments of Ophthalmology (Drs Sohn) and Neurology (Dr Farrell), University of Washington, Seattle; Oregon Retinal Degeneration Center, Casey Eye Institute, Oregon Health & Science University, Portland (Drs Francis and Weleber); Department of Ophthalmology, University of California San Francisco, San Francisco (Dr Duncan); Vitreoretinal Associates, Seattle (Dr Saperstein); Department of Ophthalmology and Visual Sciences and the Howard Hughes Medical Institute, University of Iowa, Iowa City (Dr Stone).
REFERENCES
1. Petrukhin K, Koisti MJ, Bakall B; et al. Identification of the gene responsible for Best macular dystrophy. Nat Genet. 1998;19(3):241-247.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
2. Marquardt A, Stöhr H, Passmore LA, Krämer F, Rivera A, Weber BH. Mutations in a novel gene, VMD2, encoding a protein of unknown properties cause juvenile-onset vitelliform macular dystrophy (Best's disease). Hum Mol Genet. 1998;7(9):1517-1525.
FREE FULL TEXT
3. Marmorstein AD, Marmorstein LY, Rayborn M, Wang X, Hollyfield JG, Petrukhin K. Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. Proc Natl Acad Sci U S A. 2000;97(23):12758-12763.
FREE FULL TEXT
4. Sun H, Tsunenari T, Yau KW, Nathans J. The vitelliform macular dystrophy protein defines a new family of chloride channels. Proc Natl Acad Sci U S A. 2002;99(6):4008-4013.
FREE FULL TEXT
5. Tsunenari T, Sun H, Williams J; et al. Structure-function analysis of the bestrophin family of anion channels. J Biol Chem. 2003;278(42):41114-41125.
FREE FULL TEXT
6. Marmorstein LY, Wu J, McLaughlin P; et al. The light peak of the electroretinogram is dependent on voltage-gated calcium channels and antagonized by bestrophin (best-1). J Gen Physiol. 2006;127(5):577-589.
FREE FULL TEXT
7. Rosenthal R, Bakall B, Kinnick T; et al. Expression of bestrophin-1, the product of the VMD2 gene, modulates voltage-dependent Ca2+ channels in retinal pigment epithelial cells. FASEB J. 2006;20(1):178-180.
FREE FULL TEXT
8. Yu K, Xiao Q, Cui G, Lee A, Hartzell HC. The best disease-linked Cl- channel hBest1 regulates Ca V 1 (L-type) Ca2+ channels via src-homology-binding domains. J Neurosci. 2008;28(22):5660-5670.
FREE FULL TEXT
9. Deutman AF. Electro-oculography in families with vitelliform dystrophy of the fovea: detection of the carrier state. Arch Ophthalmol. 1969;81(3):305-316.
FREE FULL TEXT
10. Krill AE, Morse PA, Potts AM, Klien BA. Hereditary vitelliruptive macular degeneration. Am J Ophthalmol. 1966;61(6):1405-1415.
WEB OF SCIENCE
| PUBMED
11. Miller SA, Bresnick GH, Chandra SR. Choroidal neovascular membrane in Best's vitelliform macular dystrophy. Am J Ophthalmol. 1976;82(2):252-255.
WEB OF SCIENCE
| PUBMED
12. Mohler CW, Fine SL. Long-term evaluation of patients with Best's vitelliform dystrophy. Ophthalmology. 1981;88(7):688-692.
WEB OF SCIENCE
| PUBMED
13. Fishman GA, Baca W, Alexander KR, Derlacki DJ, Glenn AM, Viana M. Visual acuity in patients with best vitelliform macular dystrophy. Ophthalmology. 1993;100(11):1665-1670.
WEB OF SCIENCE
| PUBMED
14. Chung MM, Oh KT, Streb LM, Kimura AE, Stone EM. Visual outcome following subretinal hemorrhage in Best disease. Retina. 2001;21(6):575-580.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
15. Frangieh GT, Green WR, Fine SL. A histopathologic study of Best's macular dystrophy. Arch Ophthalmol. 1982;100(7):1115-1121.
FREE FULL TEXT
16. O'Gorman S, Flaherty WA, Fishman GA, Berson EL. Histopathologic findings in Best's vitelliform macular dystrophy. Arch Ophthalmol. 1988;106(9):1261-1268.
FREE FULL TEXT
17. Weingeist TA, Kobrin JL, Watzke RC. Histopathology of Best's macular dystrophy. Arch Ophthalmol. 1982;100(7):1108-1114.
FREE FULL TEXT
18. Bakall B, Radu RA, Stanton JB; et al. Enhanced accumulation of A2E in individuals homozygous or heterozygous for mutations in BEST1 (VMD2). Exp Eye Res. 2007;85(1):34-43.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
19. Mullins RF, Kuehn MH, Faidley EA, Syed NA, Stone EM. Differential macular and peripheral expression of bestrophin in human eyes and its implication for best disease. Invest Ophthalmol Vis Sci. 2007;48(7):3372-3380.
FREE FULL TEXT
20. Mullins RF, Oh KT, Heffron E, Hageman GS, Stone EM. Late development of vitelliform lesions and flecks in a patient with best disease: clinicopathologic correlation. Arch Ophthalmol. 2005;123(11):1588-1594.
FREE FULL TEXT
21. Pianta MJ, Aleman TS, Cideciyan AV; et al. In vivo micropathology of Best macular dystrophy with optical coherence tomography. Exp Eye Res. 2003;76(2):203-211.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
22. Renner AB, Tillack H, Kraus H; et al. Late onset is common in best macular dystrophy associated with VMD2 gene mutations. Ophthalmology. 2005;112(4):586-592.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
23. von Rückmann A, Fitzke FW, Bird AC. In vivo fundus autofluorescence in macular dystrophies. Arch Ophthalmol. 1997;115(5):609-615.
FREE FULL TEXT
24. Bakall B, Marknell T, Ingvast S; et al. The mutation spectrum of the bestrophin protein: functional implications. Hum Genet. 1999;104(5):383-389.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
25. Caldwell GM, Kakuk LE, Griesinger IB; et al. Bestrophin gene mutations in patients with Best vitelliform macular dystrophy. Genomics. 1999;58(1):98-101.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
26. Eksandh L, Bakall B, Bauer B, Wadelius C, Andréasson S. Best's vitelliform macular dystrophy caused by a new mutation (Val89Ala) in the VMD2 gene. Ophthalmic Genet. 2001;22(2):107-115.
FULL TEXT
| PUBMED
27. Marchant D, Yu K, Bigot K; et al. New VMD2 gene mutations identified in patients affected by Best vitelliform macular dystrophy. J Med Genet. 2007;44(3):e70.
FREE FULL TEXT
28. Wabbels B, Preising MN, Kretschmann U, Demmler A, Lorenz B. Genotype-phenotype correlation and longitudinal course in ten families with Best vitelliform macular dystrophy. Graefes Arch Clin Exp Ophthalmol. 2006;244(11):1453-1466.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
29. Apushkin MA, Fishman GA, Taylor CM, Stone EM. Novel de novo mutation in a patient with Best macular dystrophy. Arch Ophthalmol. 2006;124(6):887-889.
FREE FULL TEXT
30. Krämer F, Mohr N, Kellner U, Rudolph G, Weber BH. Ten novel mutations in VMD2 associated with Best macular dystrophy (BMD). Hum Mutat. 2003;22(5):418.
PUBMED
31. Krämer F, White K, Pauleikhoff D; et al. Mutations in the VMD2 gene are associated with juvenile-onset vitelliform macular dystrophy (Best disease) and adult vitelliform macular dystrophy but not age-related macular degeneration. Eur J Hum Genet. 2000;8(4):286-292.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
32. Li Y, Wang G, Dong B; et al. A novel mutation of the VMD2 Gene in a Chinese family with best vitelliform macular dystrophy. Ann Acad Med Singapore. 2006;35(6):408-410.
WEB OF SCIENCE
| PUBMED
33. Marchant D, Gogat K, Boutboul S; et al. Identification of novel VMD2 gene mutations in patients with best vitelliform macular dystrophy. Hum Mutat. 2001;17(3):235.
PUBMED
34. Seddon JM, Sharma S, Chong S, Hutchinson A, Allikmets R, Adelman RA. Phenotype and genotype correlations in two best families. Ophthalmology. 2003;110(9):1724-1731.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
35. Sodi A, Passerini I, Simonelli F, Testa F, Menchini U, Torricelli F. A novel mutation in the VMD2 gene in an Italian family with Best maculopathy. J Fr Ophtalmol. 2007;30(6):616-620.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
36. White K, Marquardt A, Weber BH. VMD2 mutations in vitelliform macular dystrophy (Best disease) and other maculopathies. Hum Mutat. 2000;15(4):301-308.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
37. Palomba G, Rozzo C, Angius A, Pierrottet CO, Orzalesi N, Pirastu M. A novel spontaneous missense mutation in VMD2 gene is a cause of a best macular dystrophy sporadic case. Am J Ophthalmol. 2000;129(2):260-262.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
38. Schatz P, Klar J, Andréasson S, Ponjavic V, Dahl N. Variant phenotype of Best vitelliform macular dystrophy associated with compound heterozygous mutations in VMD2. Ophthalmic Genet. 2006;27(2):51-56.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
39. Lotery AJ, Munier FL, Fishman GA; et al. Allelic variation in the VMD2 gene in best disease and age-related macular degeneration. Invest Ophthalmol Vis Sci. 2000;41(6):1291-1296.
FREE FULL TEXT
40. Marchant D, Gogat K, Dureau P; et al. Use of denaturing HPLC and automated sequencing to screen the VMD2 gene for mutations associated with Best's vitelliform macular dystrophy. Ophthalmic Genet. 2002;23(3):167-174.
FULL TEXT
| PUBMED
41. Duncan JL, Zhang Y, Gandhi J; et al. High-resolution imaging with adaptive optics in patients with inherited retinal degeneration. Invest Ophthalmol Vis Sci. 2007;48(7):3283-3291.
FREE FULL TEXT
42. Spaide RF. Fundus autofluorescence and age-related macular degeneration. Ophthalmology. 2003;110(2):392-399.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
43. Marmor MF, Zrenner E, International Society for Clinical Electrophysiology of Vision. Standard for clinical electro-oculography. Arch Ophthalmol. 1993;111(5):601-604.
FREE FULL TEXT
44. Marmor MF, Zrenner E, International Society for Clinical Electrophysiology of Vision. Standard for clinical electroretinography (1999 update). Doc Ophthalmol. 1998-1999;97(2):143-156.
FULL TEXT
45. Marmor MF, Hood DC, Keating D, Kondo M, Seeliger MW, Miyake Y, International Society for Clinical Electrophysiology of Vision. Guidelines for basic multifocal electroretinography (mfERG). Doc Ophthalmol. 2003;106(2):105-115.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
46. Weleber RG. Fast and slow oscillations of the electro-oculogram in Best's macular dystrophy and retinitis pigmentosa. Arch Ophthalmol. 1989;107(4):530-537.
FREE FULL TEXT
47. Marmorstein AD, Stanton JB, Yocom J; et al. A model of best vitelliform macular dystrophy in rats. Invest Ophthalmol Vis Sci. 2004;45(10):3733-3739.
FREE FULL TEXT
48. Stöhr H, Marquardt A, Nanda I, Schmid M, Weber BH. Three novel human VMD2-like genes are members of the evolutionary highly conserved RFP-TM family. Eur J Hum Genet. 2002;10(4):281-284.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
49. Bard LA, Cross HE. Genetic counseling of families with Best macular dystrophy. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1975;79(6):OP865-OP873.
PUBMED
50. Yardley J, Leroy BP, Hart-Holden N; et al. Mutations of VMD2 splicing regulators cause nanophthalmos and autosomal dominant vitreoretinochoroidopathy (ADVIRC). Invest Ophthalmol Vis Sci. 2004;45(10):3683-3689.
FREE FULL TEXT
51. Burgess R, Millar ID, Leroy BP; et al. Biallelic mutation of BEST1 causes a distinct retinopathy in humans. Am J Hum Genet. 2008;82(1):19-31.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
52. Esumi N, Kachi S, Campochiaro PA, Zack DJ. VMD2 promoter requires two proximal E-box sites for its activity in vivo and is regulated by the MITF-TFE family. J Biol Chem. 2007;282(3):1838-1850.
FREE FULL TEXT
53. Esumi N, Oshima Y, Li Y, Campochiaro PA, Zack DJ. Analysis of the VMD2 promoter and implication of E-box binding factors in its regulation. J Biol Chem. 2004;279(18):19064-19073.
FREE FULL TEXT
54. Guziewicz KE, Zangerl B, Lindauer SJ; et al. Bestrophin gene mutations cause canine multifocal retinopathy: a novel animal model for best disease. Invest Ophthalmol Vis Sci. 2007;48(5):1959-1967.
FREE FULL TEXT
55. Querques G, Regenbogen M, Quijano C, Delphin N, Soubrane G, Souied EH. High-definition optical coherence tomography features in vitelliform macular dystrophy. Am J Ophthalmol. 2008;146(4):501-507.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
56. Spaide RF, Noble K, Morgan A, Freund KB. Vitelliform macular dystrophy. Ophthalmology. 2006;113(8):1392-1400.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
SECTION EDITOR: JANEY L. WIGGS, MD, PhD
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Three-dimensional Distribution of the Vitelliform Lesion, Photoreceptors, and Retinal Pigment Epithelium in the Macula of Patients With Best Vitelliform Macular Dystrophy
Kay et al.
Arch Ophthalmol 2011;0:archophthalmol.2011.363v1-8.
ABSTRACT
| FULL TEXT
Evaluation of Macular Structure and Function by OCT and Electrophysiology in Patients with Vitelliform Macular Dystrophy Due to Mutations in BEST1
Schatz et al.
IOVS 2010;51:4754-4765.
ABSTRACT
| FULL TEXT
|
